BTI
MYGN icon

Blue Trust Inc’s Myriad Genetics MYGN Stock Holding History

Blue Trust Inc’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$902 Hold
158
– – ﹤0.01% 2305
2026
Q1 		$711 Hold
158
– – ﹤0.01% 2303
2025
Q4 		$972 Hold
158
– – ﹤0.01% 2289
2025
Q3 		$1.14K Sell
158
-81
-34% -$481 ﹤0.01% 2293
2025
Q2 		$1.27K Sell
239
-14,128
-98% -$83.5K ﹤0.01% 2207
2025
Q1 		$127K Buy
14,367
+5,214
+57% +$62.6K ﹤0.01% 892
2024
Q4 		$125K Sell
9,153
-3,510
-28% -$64.8K ﹤0.01% 843
2024
Q3 		$310K Buy
12,663
+1,404
+12% +$38K ﹤0.01% 658
2024
Q2 		$240K Buy
11,259
+2,365
+27% +$51.9K ﹤0.01% 641
2024
Q1 		$190K Buy
8,894
+2,165
+32% +$46.5K ﹤0.01% 525
2023
Q4 		$109K Buy
6,729
+1,186
+21% +$20.5K ﹤0.01% 649
2023
Q3 		$128K Buy
5,543
+4,431
+398% +$84.3K ﹤0.01% 552
2023
Q2 		$26K Sell
1,112
-10,266
-90% -$224K ﹤0.01% 950
2023
Q1 		$165K Buy
11,378
+2,350
+26% +$47.7K ﹤0.01% 607
2022
Q4 		$172K Buy
9,028
+4,589
+103% +$85.5K ﹤0.01% 504
2022
Q3 		$81K Buy
4,439
+775
+21% +$17.8K ﹤0.01% 604
2022
Q2 		$92K Buy
+3,664
New +$76.1K ﹤0.01% 519

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Blue Trust Inc's MYGN Position: Q2 2026 in Review

Blue Trust Inc held its Myriad Genetics (MYGN) position steady in Q2 2026 at 158 shares worth $902. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Blue Trust Inc first reported a position in MYGN in Q2 2022 and has held it in 17 quarters since. The position peaked at $310K in Q3 2024. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Blue Trust Inc held 158 shares of Myriad Genetics worth $902 as of Q2 2026.
  • Blue Trust Inc left its Myriad Genetics share count unchanged in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2305 holding.
  • Blue Trust Inc first reported a position in Myriad Genetics in Q2 2022 and has held it in 17 quarters since.
  • Blue Trust Inc's Myriad Genetics position peaked at $310K in Q3 2024.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.